Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule
暂无分享,去创建一个
T. Yap | Taiying Chen | Jeremy Clark | J. Bono | R. Riisnaes | J. Barriuso | R. Savage | M. Wright | I. Ledaki | D. Harris